Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

Prior treatment

• Prior treatment with auristatin-derived drugs s (eg, MMAE and monomethyl auristatin F \[MMAF\]).
• Received antitumor therapy within 4 weeks prior to the first dose or 5 half-lives, whichever is shorter.
• History of uncontrolled diabetes mellitus or diabetic neuropathy within 3 months before the first dose of study treatment.
• Previous drug-induced interstitial lung disease (ILD) or active ILD.
• Prior treatment with MUC16- or NaPi2b-targeting agents.

Other illness

• Infection of active hepatitis B, active hepatitis C, or HIV.
• History of recurrent gastrointestinal (GI) obstruction.
• Patients with more than one cancer.
• History of severe cardiovascular diseases.
• Known allergic reactions to any component of ARR-002.
• Ocular conditions such as keratitis or corneal ulceration, monocularity, corneal transplantation, uncontrolled retinopathy, wet macular degeneration, uveitis, papilledema, or optic disc disorder.

Lab values

• Any other diseases, pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding

Other

• Symptomatic Central nervous system and/or meninges metastasis.
• Poorly controlled pleural, peritoneal, and pelvic effusion, or combined pericardial effusion.
• Grade ≥ 2 peripheral neuropathy
• Current use of anticoagulants or thrombolytic agents for therapeutic purposes.
• Other situations that are not suitable to participate a clinical trial per investigator's judgement.

• Patients with histologically and cytologically confirmed advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer, and platinum resistant who have failed or intolerant to standard therapy, or without alternative standard therapy.
• Patients must have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
• Tumor specimen available for testing, or agree to biopsy at baseline.
• The score of Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Life expectancy ≥ 12 weeks.
• Organ functions and coagulation function must meet the basic requirements.
• Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment.